未登录

J

Jill Barber

centre for applied pharmacokinetic research

H指数:35

被引数:5,158

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The New Spine of Access to the Brain’s Secrets: Extracellular Vesicles from Cerebrospinal Fluid Liquid Biopsies in CNS Diseases and Blood–Brain Barrier Research

通往大脑秘密的新途径：中枢神经系统疾病和血脑屏障研究中脑脊液液体活检的细胞外囊泡

Molecular Neurobiology

IF4.3

2026-07-230

OAAI

Unveiling Hepatic Protein Alterations in Neonatal and Infant Biliary Atresia

揭示新生儿和婴儿胆道闭锁中的肝脏蛋白质改变

Clinical Pharmacology & Therapeutics

IF5.5

2026-03-040

OAAI

Overlooked aspects of scaling enzyme activity through abundance across tissues and individuals: Insights from kcat measurements in matched liver and intestinal samples

Drug Metabolism and Disposition

IF4

2025-12-290

OAAI

Changes in Protein Expression of Renal Drug Transporters and Drug-Metabolizing Enzymes in Autosomal Dominant Polycystic Kidney Disease Patients

常染色体显性多囊肾病患者的肾脏药物转运体和药物代谢酶蛋白表达变化

Clinical Pharmacology & Therapeutics

IF5.5

2025-05-150

OAAI

Variability in intestinal drug metabolizing enzymes and transporters in Crohn's disease and potential impact on oral drug absorption

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2025-03-010

OAAI

The quest to define cancer-specific systems parameters for personalized dosing in oncology

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY

IF3.4

2025-03-010

PRE

Transporter expressions as part of required scaling factor to support in vitro in vivo extrapolation for blood-brain barrier drug permeability

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

IF4.7

2025-01-010

OA

Establishing a physiologically based pharmacokinetic framework for aldehyde oxidase and dual aldehyde oxidase-CYP substrates

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2024-10-231

OAAI

Complementarity of two proteomic data analysis tools in the identification of drug-metabolising enzymes and transporters in human liver

MOLECULAR OMICS

IF2.4

2024-01-010

OA

Toward systems-informed models for biologics disposition: covariates of the abundance of the neonatal Fc Receptor (FcRn) in human tissues and implications for pharmacokinetic modelling

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

IF4.7

2023-03-016

OA

Proteomic quantification of receptor tyrosine kinases involved in the development and progression of colorectal cancer liver metastasis

FRONTIERS IN ONCOLOGY

IF3.3

2023-02-204

OAAI

Computational Studies on Selected Macrolides Active against Escherichia coli Combined with the NMR Study of Tylosin A in Deuterated Chloroform

IF4.6

2022-10-262

OAAI

Quantitative Assessment of the Impact of Crohn's Disease on Protein Abundance of Human Intestinal Drug-Metabolising Enzymes and Transporters

JOURNAL OF PHARMACEUTICAL SCIENCES

IF3.8

2022-10-0111

OAAI

Quantitative Proteomics of Hepatic Drug-Metabolizing Enzymes and Transporters in Patients with Colorectal Cancer Metastasis

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2022-05-2112

OAAI

Proteomics of colorectal cancer liver metastasis: A quantitative focus on drug elimination and pharmacodynamics effects

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2021-12-0317

OAAI

Selected Derivatives of Erythromycin B-In Silico and Anti-Malarial Studies

红霉素B的某些衍生物-在Silico和抗疟疾研究中

IF3.2

2021-11-181

OAAI

Quantitative Proteomic Map of Enzymes and Transporters in the Human Kidney: Stepping Closer to Mechanistic Kidney Models to Define Local Kinetics

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2021-09-0720

OAAI

Quantification of Proteins Involved in Intestinal Epithelial Handling of Xenobiotics

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2020-12-0526

OAAI

Mass spectrometry-based abundance atlas of ABC transporters in human liver, gut, kidney, brain and skin

IF3

2020-12-0323

OAAI

Liquid Biopsy Enables Quantification of the Abundance and Interindividual Variability of Hepatic Enzymes and Transporters

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2020-11-2576

OAAI